Curcumin Blocks Multiple Sites of the TGF-beta Signaling Cascade in Renal Cells
Overview
Authors
Affiliations
Background: Over-expression of transforming growth factor-beta (TGF-beta) contributes greatly to fibrotic kidney disease. The activator protein-1 (AP-1) inhibitor curcumin, a polyphenolic compound derived from Curcuma longa, has been shown to reduce collagen accumulation in experimental pulmonary fibrosis. Here, we investigate curcumin's ability to modulate TGF-beta's profibrotic actions in vitro.
Methods: NRK49F rat renal fibroblasts were stimulated with TGF-beta (5 ng/mL), and the effects of curcumin on TGF-beta-regulated genes, TGF-beta receptors, and phosphorylated SMAD isoforms were analyzed by Northern blotting, enzyme-linked immunosorbent assay (ELISA), and Western blotting. The effects of c-jun depletion on TGF-beta-regulated gene and protein expression were analyzed with RNAi.
Results: When applied 30 minutes before TGF-beta, curcumin dose dependently and dramatically reduced TGF-beta-induced increases in plasminogen activator inhibitor-1 (PAI-1), TGF-beta1, fibronectin (FN) and collagen I (Col I) mRNA, and in PAI-1 and fibronectin protein. Prolonged curcumin treatment (>6 h) significantly reduced TGF-beta receptor type II levels and SMAD2/3 phosphorylation in response to added TGF-beta. Depletion of cellular c-jun levels with a RNAi method mimicked the effects of curcumin on expression of TGF-beta1, FN, and Col I, but not PAI-1.
Conclusion: Curcumin blocks TGF-beta's profibrotic actions on renal fibroblasts through down-regulation of TbetaRII, and through partial inhibition of c-jun activity. These in vitro data suggest that curcumin might be an effective antifibrotic drug in the treatment of chronic kidney disease.
Ma Y, Ye S, Sun K, Gu Y Front Pharmacol. 2024; 15:1344333.
PMID: 38708080 PMC: 11066239. DOI: 10.3389/fphar.2024.1344333.
Afshari H, Noori S, Zarghi A Inflammopharmacology. 2023; 31(5):2541-2555.
PMID: 37452228 DOI: 10.1007/s10787-023-01281-2.
Rai A, Qazi S, Raza K Indian J Otolaryngol Head Neck Surg. 2022; 74(Suppl 2):2111-2121.
PMID: 36452628 PMC: 9702157. DOI: 10.1007/s12070-020-02014-5.
Sanaye M, Sathyapal G, Kulkarni Y J Diabetes Metab Disord. 2022; 21(2):1349-1358.
PMID: 36404856 PMC: 9672202. DOI: 10.1007/s40200-022-01065-5.
Complementary therapies for patients with systemic sclerosis.
Showalter K, Hoffmann A, DeCredico N, Thakrar A, Arroyo E, Goldberg I J Scleroderma Relat Disord. 2022; 4(3):187-199.
PMID: 35382503 PMC: 8922560. DOI: 10.1177/2397198319833503.